The clinical outcome of pembrolizumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a single center, real world study in China

Zongyu Fan; Zongyu Fan; Zongyu Fan; Rongrong Hui; Rongrong Hui; Houyu Ju; Houyu Ju; Houyu Ju; Yunteng Wu; Yunteng Wu; Yunteng Wu; Xuhui Ma; Xuhui Ma; Xuhui Ma; Hao Song; Hao Song; Hao Song; Yang Liu; Yang Liu; Yang Liu; Mengyu Rui; Mengyu Rui; Mengyu Rui; Xinrong Geng; Xinrong Geng; Xinrong Geng; Minqi Zhao; Minqi Zhao; Yingye Xin; Yingye Xin; Dongliang Wei; Dongliang Wei; Dongliang Wei; Guoxin Ren; Guoxin Ren; Guoxin Ren

doi:10.3389/fonc.2024.1360657

Frontiers in Oncology (Feb 2024)

The clinical outcome of pembrolizumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a single center, real world study in China

Zongyu Fan,
Zongyu Fan,
Zongyu Fan,
Rongrong Hui,
Rongrong Hui,
Houyu Ju,
Houyu Ju,
Houyu Ju,
Yunteng Wu,
Yunteng Wu,
Yunteng Wu,
Xuhui Ma,
Xuhui Ma,
Xuhui Ma,
Hao Song,
Hao Song,
Hao Song,
Yang Liu,
Yang Liu,
Yang Liu,
Mengyu Rui,
Mengyu Rui,
Mengyu Rui,
Xinrong Geng,
Xinrong Geng,
Xinrong Geng,
Minqi Zhao,
Minqi Zhao,
Yingye Xin,
Yingye Xin,
Dongliang Wei,
Dongliang Wei,
Dongliang Wei,
Guoxin Ren,
Guoxin Ren,
Guoxin Ren

Affiliations

Zongyu Fan: Department of Oral Maxillofacial‐Head and Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Zongyu Fan: Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, National Clinical Research Center of Stomatology, Shanghai, China
Zongyu Fan: National Clinical Research Center of Stomatology, Shanghai, China
Rongrong Hui: Department of Oral Maxillofacial‐Head and Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Rongrong Hui: School of Stomatology, Weifang Medical University, Weifang, China
Houyu Ju: Department of Oral Maxillofacial‐Head and Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Houyu Ju: Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, National Clinical Research Center of Stomatology, Shanghai, China
Houyu Ju: National Clinical Research Center of Stomatology, Shanghai, China
Yunteng Wu: Department of Oral Maxillofacial‐Head and Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Yunteng Wu: Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, National Clinical Research Center of Stomatology, Shanghai, China
Yunteng Wu: National Clinical Research Center of Stomatology, Shanghai, China
Xuhui Ma: Department of Oral Maxillofacial‐Head and Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Xuhui Ma: Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, National Clinical Research Center of Stomatology, Shanghai, China
Xuhui Ma: National Clinical Research Center of Stomatology, Shanghai, China
Hao Song: Department of Oral Maxillofacial‐Head and Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Hao Song: Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, National Clinical Research Center of Stomatology, Shanghai, China
Hao Song: National Clinical Research Center of Stomatology, Shanghai, China
Yang Liu: Department of Oral Maxillofacial‐Head and Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Yang Liu: Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, National Clinical Research Center of Stomatology, Shanghai, China
Yang Liu: National Clinical Research Center of Stomatology, Shanghai, China
Mengyu Rui: Department of Oral Maxillofacial‐Head and Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Mengyu Rui: Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, National Clinical Research Center of Stomatology, Shanghai, China
Mengyu Rui: National Clinical Research Center of Stomatology, Shanghai, China
Xinrong Geng: Department of Oral Maxillofacial‐Head and Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Xinrong Geng: Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, National Clinical Research Center of Stomatology, Shanghai, China
Xinrong Geng: National Clinical Research Center of Stomatology, Shanghai, China
Minqi Zhao: Department of Oral Maxillofacial‐Head and Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Minqi Zhao: School of Stomatology, Weifang Medical University, Weifang, China
Yingye Xin: School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China
Yingye Xin: Department of Orthopedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai, China
Dongliang Wei: Department of Oral Maxillofacial‐Head and Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Dongliang Wei: Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, National Clinical Research Center of Stomatology, Shanghai, China
Dongliang Wei: National Clinical Research Center of Stomatology, Shanghai, China
Guoxin Ren: Department of Oral Maxillofacial‐Head and Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Guoxin Ren: Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology, National Clinical Research Center of Stomatology, Shanghai, China
Guoxin Ren: National Clinical Research Center of Stomatology, Shanghai, China

DOI: https://doi.org/10.3389/fonc.2024.1360657
Journal volume & issue: Vol. 14

Abstract

Read online

BackgroundThe KEYNOTE-048 and KEYNOTE-040 study have demonstrated the efficacy of pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC), we conducted this real-world study to investigate the efficacy of pembrolizumab in patients with R/M HNSCC.MethodsThis is a single-center retrospective study conducted in the Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (Shanghai, China). Between December 2020 and December 2022, a total of 77 patients with R/M HNSCC were included into analysis. The primary endpoint of the study was overall survival (OS), and the secondary endpoints were progression-free survival (PFS), overall response rate (ORR)and toxicity.Efficacy was assessed according to RECIST version 1.1.SPSS 27.0 and GraphPad Prism 8.0 software were utilized to perform the statistical analysis.ResultsBy the cut-off date (February 28, 2023), the median OS,PFS and ORR were 15.97 months,8.53 months and 48.9% in patients treated with the pembrolizumab regimen in the first line therapy. Among these patients, 17 patients received pembrolizumab with cetuximab,and 18 received pembrolizumab with chemotherapy.We observed no significant differences between two groups neither in median OS (13.9 vs 19.4 months, P=0.3582) nor PFS (unreached vs 8.233 months, P= 0.2807). In the ≥2nd line therapy (n=30), the median OS, PFS and ORR were 5.7 months, 2.58 months and 20% respectively. Combined positive score (CPS) was eligible from 54 patients. For first line therapy, the median OS and PFS were 14.6 and 8.53 months in patients with CPS ≥1, and median OS and PFS were 14.6 and 12.33 months in patients with CPS ≥20. The immune-related adverse events (irAEs) were occurred in the 31 patients (31/77, 40.26%), and the most common potential irAEs were hypothyroidism (25.97%), and pneumonitis (7.79%).ConclusionOur real-world results indicated that pembrolizumab regimen is a promising treatment in patients with R/M HNSCC

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords